GlassScriptPhysician profile
Muhammad Naeem
NPI 1508869116
$2,745.05
in general payments reported to CMS, 2019-2025
32 companies · $348 in 2025
The $348 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $135 · 2021: $682 · 2022: $721 · 2023: $404 · 2024: $311 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,062.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $790.94 | 2021-2025 | |
| Lundbeck LLC | $253.79 | 2019-2025 | Vyepti |
| Pfizer INC. | $211.80 | 2023-2025 | |
| Biogen, INC. | $199.73 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $152.99 | 2019-2025 | |
| Eisai INC. | $119.92 | 2022 | |
| Sk Life Science, INC. | $94.57 | 2021-2023 | |
| Ucb, INC. | $94.46 | 2019-2025 | Rystiggo |
| Biohaven Pharmaceutical Holding Company LTD. | $77.54 | 2022 | |
| Upsher-Smith Laboratories LLC | $73.61 | 2019-2022 | |
| Harmony Biosciences LLC | $59.38 | 2022 | |
| Hologic Sales and Service, LLC | $56.96 | 2022-2023 | Thinprep 2000 Processor |
| Amgen INC. | $56.30 | 2021-2022 | |
| Lilly USA, LLC | $47.38 | 2024 | Amyvid, Mounjaro, Kisunla |
| Celgene Corporation | $44.97 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $42.41 | 2020-2025 | |
| Amneal Pharmaceuticals LLC | $39.84 | 2021-2024 | Rytary |
| Kyowa Kirin, INC. | $31.57 | 2020-2021 | |
| Novo Nordisk INC | $30.49 | 2023 | Rybelsus, Ozempic, Wegovy |
| Biohaven Pharmaceuticals, INC. | $29.76 | 2021 | |
| Sumitomo Pharma America, INC. | $29.39 | 2023 | Aptiom |
| Teva Pharmaceuticals USA, INC. | $29.06 | 2020 | |
| Horizon Therapeutics Plc | $27.72 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $22.04 | 2022 | |
| Genzyme Corporation | $18.40 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.45 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.38 | 2022 | |
| Neurelis, INC. | $16.71 | 2021 | |
| Adamas Pharmaceuticals, INC. | $16.16 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.65 | 2022 | |
| Livanova USA, INC. | $14.43 | 2020 | |
| Currax Pharmaceuticals LLC | $12.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Naeem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.